LivaNova PLC (NASDAQ:LIVN) Receives $61.17 Consensus Target Price from Brokerages

LivaNova PLC (NASDAQ:LIVN) has earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $61.17.

Several research firms have issued reports on LIVN. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. The Goldman Sachs Group cut their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Stifel Nicolaus lowered their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th.

LivaNova Stock Performance

Shares of LIVN opened at $35.10 on Friday. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 83.57 and a beta of 0.84. The firm has a fifty day simple moving average of $37.76 and a 200 day simple moving average of $45.34. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 12 month low of $32.48 and a 12 month high of $64.07.

Institutional Trading of LivaNova

A number of large investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB grew its stake in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after acquiring an additional 12,470 shares during the period. Harbor Capital Advisors Inc. bought a new position in LivaNova during the fourth quarter worth about $1,954,000. KBC Group NV increased its stake in shares of LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after purchasing an additional 56,580 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of LivaNova by 29.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after purchasing an additional 1,424 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.